1. 364TiPAnti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97. (23rd October 2018) Authors: Decker, T; Denkert, C; Lübbe, K; Müller, V; Mundhenke, C; Furlanetto, J; Schmidt, M; Thill, M; Tierbach, V; Seither, F; Loibl, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗